Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Real-World Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten - a Single-Center Descriptive Study

The purpose of this study is to evaluate the real-world outcomes of individuals diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten at the Hospital of The University of Pennsylvania in the US

Inclusion Criteria:

• Age ≥ 18 years at index date
• Prescription of mavacamten for the treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM)
• ≥ 4 weeks of follow-up after prescription of mavacamten

Exclusion Criteria:

• Data collection as part of a clinical trial during the study period
• Current participation in a myosin inhibitor clinical trial